https://ntp.niehs.nih.gov/go/28756

Dicyclohexylcarbodiimide: Target Organs and Levels of Evidence for GMM-09

Toxicology Studies of Dicyclohexylcarbodiimide (CASRN 538-75-0) in F344/N Rats, B6C3F1 Mice, and Genetically Modified (FVB Tg.AC HEMIZYGOUS) Mice and Carcinogenicity Study of Dicyclohexylcarbodiimide in Genetically Modified [B6.129-Trp53tm1Brd (N5) Haploinsufficient] Mice (Dermal Studies)

Chemical (Study Title)
CASRN 		Peer Review Date Route/Exposure Levels Study Laboratory
Dicyclohexylcarbodiimide
538-75-0 		08/28/2006 Topical Application
0, 0.75, 1.5, 3, 6, or 12 mg/kg; 15/group		 BioReliance, Inc

Levels of evidence information for Dicyclohexylcarbodiimide in Female Tg.AC Hemizygous Mice
  Female Tg.AC Hemizygous Mice
  20 Week
Neoplastic Lesions
  • Skin (site of application): squamous cell papilloma (0/10, 0/10, 1/10, 3/10, 6/10, 8/10)
Non-Neoplastic Lesions
  • Skin (site of application): chronic active inflammation of the dermis; epidermal hyperplasia

Levels of evidence information for Dicyclohexylcarbodiimide in Female p53 Haploinsufficient Mice
  Female p53 Haploinsufficient Mice
  27 Week
Levels of Evidence No evidence
Neoplastic Lesions None
Non-Neoplastic Lesions
  • Skin (site of application): focal epidermal hyperplasia; focal chronic active inflammation of the dermis; focal ulcer; focal chronic active inflammation of the subcutaneous tissue